Recombinant growth hormone at supraphysiological doses increases IGFBP and ALS, thereby increasing ternary complex and preventing interaction with insulin receptor ultimately decreasing chances of hypoglycemia [11–13]. The gene discussed is GH1; the disease is Hypoglycemia.